Cell-based assay services incorporating Horizon’s
isogenic cell line technology

Through Ubiquigent’s relationship with Horizon and access to their cell line technology platforms we are delighted to offer a range of service capabilities to assist you in your ubiquitin system basic and drug discovery applied research including:

• pathway validation
• target discovery and validation
• compound mechanism of action validation
• biomarker discovery and validation

Access to genetically defined isogenic cell lines including knock-outs, knock-ins and site directed mutations

Ubiquigent has access to Horizon’s comprehensive array of ubiquitin system knock out genetically defined and highly validated human cell lines for application in our ubiquitin system research and drug discovery services (learn more about Horizon cell lines here and click here for a full listing of cell lines available as part of Ubiquigent’s drug discovery services).  For optimal experimental control, the isogenic control (wild type) cell line is also available with each modified/mutant cell line selected.  Furthermore if the cell line that you need is not listed then through our relationship with Horizon we can have customised lines generated to provide you with the precise assay service that you require.  By way of example such customised cell lines may carry active site directed mutations or tags on specific ubiquitin system or ubiquitin system target (substrate) proteins or reporters linked to ubiquitin system gene promoters.

The Horizon  proprietary HAP1 cell line is derived from the male chronic myelogenous leukaemia (CML) cell line KBM-7.  Click here for further information about the HAP1 cell line.

HAP1 cell lines available off the shelf for use in Ubiquigent’s drug discovery services:

Ubiquitin E2 Conjugating Enzymes

Deubiquitylating Enzymes (DUBs)

Sumoylation enzyme

Autophagy enzymes

DNA damage pathways

Parkinson’s disease

Please enquire if you require the generation of any cell line not listed above.

Please click here for a list of publications referencing the application of Horizon’s HAP1 cell lines.

Access to the ‘gene-trap’ cell-based platform in support of target identification and validation

Determine the genes involved in your pathway of interest in order – for example – to identify potential drug targets and/or synthetic lethality opportunities.  Interrogate a library of cell lines – contained within a single vial and in which 99% of the expressed genes have been inactivated – with your cell-based assay of choice.  Your assay simply requires the capability to select cells carrying the mutation of interest from the parent population; for example by proliferation of the mutant line or selection by FACS.  Furthermore by utilising Horizons´s platform we can also offer ‘layering’ of mutations into this library of cells such that the library carries for example a mutation in a ubiquitin system protein of interest and/or a reporter gene reporting the activity of a promoter of choice.  We will then report to you the identity of the inactivated genes that were present in the cells isolated from the library using your cell-based assay of choice.  This approach may identify targets or indeed entire pathways whose inactivation leads to the phenotype being selected in the assay supporting for example pathway elucidation, target identification, target validation and synthetic lethality identification opportunity objectives.

Please contact us here for advice so that with you we can design customised ubiquitin system cell based models and assays utilising Horizon’s unique cell line and ‘gene trapping’ platforms to address your specific question as part of Ubiquigent’s drug discovery services.  For your convenience and by way of example we have below outlined typical ‘question-solution’ case studies that you might like to review and consider as you plan the experiments that you’d like us to conduct on your behalf.

 

 

---